

+ Precision powered performance

Aiming for a new era of performance
and value for the knee

Smith+Nephew



WEREWOLF⁺
FASTSEAL 6.0
Hemostasis Wand



KNEE



The data...

Traditionally, a tourniquet is used during a total knee arthroplasty (TKA) to create a bloodless surgical field and reduce intraoperative bleeding. However, what does the data from a systematic literature review and meta-analysis of 40 studies suggest about the use of tourniquet vs. non-tourniquet?



Blood loss

No statistically different total blood loss in non-tourniquet than tourniquet procedures¹



Pain

Using a tourniquet, post-operative pain for a patient is significantly higher at 24 hours ($p=0.0007$), 72 hours ($p<0.0001$) and up to 3 weeks ($p\leq 0.0221$)¹



Range of motion

Using a tourniquet, patients had:

- 4.5° reduced range of motion at 3 days post-operatively ($p<0.0001$)¹
- 3.4° reduced range of motion at 4-6 weeks postoperatively ($p<0.034$)¹



Length of stay

Using a tourniquet, the patient has 0.5 days longer length of stay ($p=0.0172$)¹

50%

Greater risk

Using a tourniquet, the patient is at 50% greater risk of deep vein thrombosis (DVT) ($p=0.0039$)¹

FASTSEAL 6.0 Hemostasis Wand

Experience the power of the FASTSEAL 6.0 Wand using the WEREWOLF Controller – a single unit available to use for all your Sports Medicine, ENT and orthopedic procedures.



Handle geometry includes grip features that minimize FASTSEAL 6.0 device slipping or rotating in the hand during use⁶



200°C
less

The combination of saline and radiofrequency energy provides an average peak temperature of $96 \pm 3^\circ\text{C}^*$ – approximately 200°C less than monopolar electrocautery²⁻⁴

Additionally, the FASTSEAL 6.0 device operates at a peak current limit of 1.5 amps compared to 3.2 amps for Aquamantys™ 6.0, to limit thermal energy potential of saline.⁵

*One device tested 30 times

Shown to have less visible charring of soft tissue than a monopolar electrocautery device^{7**}

**As demonstrated ex vivo at maximum setting, single device tested 30 times



Figures: Typical appearance of FASTSEAL 6.0 (left) and monopolar electrocautery device (right) coagulation treatments in bovine myocardium (beef heart) soft tissue model.⁷



An auxiliary MAX control allows the user to immediately access the MAX power and flow settings when required.

WEREWOLF[◇] Controller

Experience the power of the FASTSEAL 6.0 Wand using the WEREWOLF Controller, a single unit is available to use for all your Sports Medicine, ENT and orthopedic procedures.

The FASTSEAL 6.0 Wand requires less time between controller connection and activation than Aquamantys™ 6.0 with Aquamantys Pump Generator system^{8,9*}

*As per in the Aquamantys Pump Generator User Guide

Flow rate

- Range of saline flow rate range from 1 (lowest) to 5 (highest)
- Default setting is 3

Priming button

- On the WEREWOLF Controller, the FASTSEAL 6.0 Wand has been shown to prime in 14 seconds^{8,9}



Coagulation level

- Rate of coagulation levels from 110 (lowest) to a maximum of 200 (highest)
- Default setting is 170



Setting preferences

- Volume adjustment
- Language preferences
- Foot pedal and handpiece preferences

Foot pedal plug-in

Ordering information

WEREWOLF [®] FASTSEAL 6.0	
Reference	Description
72290146	WEREWOLF+ COBLATION [®] System
72290042	WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Learn more at [smith-nephew.com](https://www.smith-nephew.com)

Distributed by:
Smith & Nephew, Inc.
150 Minuteman Road
Andover, MA 01810
USA

www.smith-nephew.com
T +978 749 1000
US Customer Service:
+1 800 343 5717

Manufactured by:
ArthroCare Corporation
7000 West William
Cannon Drive
Austin, TX 78735, USA

[®]Trademark of Smith+Nephew.
All trademarks acknowledged.
©2024 Smith+Nephew. All rights reserved. 30797 V3 12/24

References

1. Smith+Nephew 2021. Tourniquet-versus tourniquet-less total knee arthroplasty: A systematic review with meta-analysis of patient outcomes. Internal Report EA/SPM/COBLATION/007/v1
2. Marulanda GA, Ulrich SD, Seyler TM, Delanois RE, Mont MA. Reductions in blood loss with a bipolar sealer in total hip arthroplasty. *Expert Rev Med Devices*. 2008;5(2):125-131.
3. Derman PB, Kamath AF, Lee GC. Saline-coupled bipolar sealing in revision total knee arthroplasty for infection. *Am J Orthop* (Belle Mead NJ). 2013;42(9):407-411.
4. Smith+Nephew 2021. Report, Peak Temperature Comparative Study, FASTSEAL 6.0 and Aquamantys 6.0. Internal Report. 110180-02 Rev A.
5. Smith+Nephew 2021. FASTSEAL 6.0 Wand Current Limit Safety Feature. Internal Report. 110183 Rev A.
6. Smith+Nephew 2021. Arthroplasty Coagulation System Summative / Human Factors Validation. Internal Report. 110154-01 Rev A.
7. Smith+Nephew 2021. Engineering Report, Soft Tissue Visual Charring Study, FASTSEAL 6.0 and Bovie-Style Device. Internal Report. 21-0005-01 Rev A.
8. Smith+Nephew 2021. Design Verification Report: Challenge Condition, Expected Use & Every Tissue Every Level. Internal Report. 110127-01 Rev A.
9. Smith+Nephew 2021. Priming time associated with the Aquamantys Pump Generator. Internal Report. EO.SPM.PCS.037.001.v1.